FDA D.I.S.C.O.: Avelumab in Merkel Cell Carcinoma Transcript
Share:
Listens: 0
About
FDA D.I.S.C.O.: Avelumab in Merkel Cell Carcinoma FDA medical oncologists discuss the agency’s March 23, 2017, approval of avelumab the treatment of patients 12 years and older with metastatic Merkel cell carcinoma.
FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)
Science
FDA D.I.S.C.O.: Avelumab in Merkel Cell Carcinoma FDA medical oncologists discuss the agency’s March 23, 2017, approval of avelumab the treatment of patients 12 years and older with metastatic Merkel cell carcinoma.